Allarity Therapeutics (ALLR) vs BeyondSpring (BYSI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Allarity Therapeutics (ALLR) has outperformed BeyondSpring (BYSI) over the past year, losing 25.9% versus a loss of 82.8%. BeyondSpring is the larger company by market cap ($13.7 million vs $12.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALLR | BYSI |
|---|---|---|
| Share price | $0.785 | $0.33 |
| Market cap | $12.56M | $13.66M |
| 1-day change | -9.25% | -24.49% |
| YTD return | -27.31% | -79.75% |
| 1-year return | -25.94% | -82.77% |
| 5-year return | — | -97.70% |
| EPS (TTM) | $-0.79 | $-0.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $320.00K | $0 |
| Net income (latest FY) | $-11.23M | $-1.01M |
| Operating margin | -3939.06% | — |
| Net margin | -3509.69% | — |
| 52-week high | $1.84 | $2.44 |
| 52-week low | $0.769 | $0.299 |
| Distance from 52-week high | -57.34% | -86.48% |
| Analyst consensus | none | — |
| Avg. price target upside | +1301.27% | — |
| Average volume | 131.74K | 261.79K |
| Shares outstanding | 16.00M | 41.41M |
| Employees | 7 | 44 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ALLR has outperformed BYSI by 56.8 percentage points over the past year.
About Allarity Therapeutics
ALLR stock →Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About BeyondSpring
BYSI stock →BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates through two segments: the Plinabulin pipeline and the TPD platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 44 employees
ALLR vs BYSI FAQ
Which is bigger, Allarity Therapeutics or BeyondSpring?
BeyondSpring (BYSI) is larger, with a market capitalization of $13.66M compared with $12.56M for Allarity Therapeutics (ALLR).
Which stock has performed better over the past year, ALLR or BYSI?
ALLR returned -25.94% over the past 12 months, compared with -82.77% for BYSI (price return, excluding dividends). Past performance does not predict future results.
Are Allarity Therapeutics and BeyondSpring in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.